13 Best Long-Term Penny Stocks to Buy According to Analysts

Page 11 of 12

2. Atai Life Sciences (NASDAQ:ATAI)

Stock Price: $2.33

Analyst Upside: 329.18%

Number of Hedge Fund Holders: 14

Atai Life Sciences (NASDAQ:ATAI) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 6, analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Atai Life Sciences (NASDAQ:ATAI), retaining the price target of $6.00. The analyst gave the optimistic rating due to various factors, including the strategic merger between Beckley Psytech and Atai Life Sciences (NASDAQ:ATAI).

Expected to close in H2 2025, the merger is expected to strengthen Atai Life Sciences’ (NASDAQ:ATAI) pipeline through Beckley’s advanced short-acting psychedelic programs, including BPL-003. The merger is, however, contingent upon the success of the Phase 2b trial for BPL-003 in treatment-resistant depression, with results expected to be released by mid-2025.

The analyst further reasoned that Atai Life Sciences’ (NASDAQ:ATAI) financial position is further bolstered by the concurrent $30 million private placement, which is independent of the merger. The company also has a robust pipeline, such as its internal VLS-01 DMT program, which, according to Okunewitch, can provide potential benefits in the psychedelic therapy market.

Headquartered in Germany, Atai Life Sciences (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company focused on treating mental health disorders.

Page 11 of 12